Pergolida [Inn-Spanish] en es it fr

Pergolida [Inn-Spanish] Brand names, Pergolida [Inn-Spanish] Analogs

Pergolida [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Pergolida [Inn-Spanish] Chemical_Formula


Pergolida [Inn-Spanish] RX_link

Pergolida [Inn-Spanish] fda sheet

Pergolida_[Inn-Spanish] FDA

Pergolida [Inn-Spanish] msds (material safety sheet)

Pergolida_[Inn-Spanish] MSDS

Pergolida [Inn-Spanish] Synthesis Reference

No information avaliable

Pergolida [Inn-Spanish] Molecular Weight

314.489 g/mol

Pergolida [Inn-Spanish] Melting Point

207.5 oC

Pergolida [Inn-Spanish] H2O Solubility

No information avaliable

Pergolida [Inn-Spanish] State


Pergolida [Inn-Spanish] LogP


Pergolida [Inn-Spanish] Dosage Forms


Pergolida [Inn-Spanish] Indication

Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.

Pergolida [Inn-Spanish] Pharmacology

Pergolide is an ergot derivative dopamine receptor agonist at both D1 and D2 receptor sites. Pergolide is 10 to 1,000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system.

Pergolida [Inn-Spanish] Absorption

Significant amount may be absorbed (evidence on bioavailability still lacking).

Pergolida [Inn-Spanish] side effects and Toxicity

Oral, rat LD50: 15 mg/kg. Symptoms of overdose include nausea, vomiting, convulsions, decreased blood pressure, and CNS stimulation.

Pergolida [Inn-Spanish] Patient Information

Pergolida [Inn-Spanish] Organisms Affected

Humans and other mammals